Stoke Therapeutics, Inc. STOK
Set alert
At close · Oct 30
After hours · Oct 30, 4:33 PM ET
- YTD
- -17.17%
- 1 year
- -17.07%
- Open
- 26.04
- Prev close
- 26.35
- Mkt cap
- 1.70B
- Vol
- 1.86M
- Avg vol
- 1.05M
- EPS
- -3.81
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 25.86
- High
- 26.72
- Forward P/E
- -7.45
- Beta
- 1.26
- Short ratio
- 10.28
- Inst. own
- 125.47%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 15, 2027
- 50-d avg
- 27.53
- 200-d avg
- 30.94
- 1y target
- 46.46
News
3 days ago seekingalpha.com
Stoke Therapeutics, Inc. (STOK) Q3 2026 Earnings Call Transcript
Stoke Therapeutics, Inc. (STOK) Q3 2026 Earnings Call Transcript
3 days ago marketbeat.com
Stoke Therapeutics Q3 Earnings Call Highlights
Stoke Therapeutics NASDAQ: STOK said its Phase III EMPEROR trial of zorevunersen in Dravet syndrome is advancing toward a planned third-quarter 2027 data readout, while the company prepares for a…
3 days ago zacks.com
Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $1.08 per share versus the Zacks Consensus Estimate of a loss of $0.88. This compares to a loss of $0.65 per share a year ago.
3 days ago benzinga.com
Stoke Therapeutics Q3 2026 Earnings Call Transcript
Stoke Therapeutics (NASDAQ:STOK) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
-
3 days ago benzinga.com
Stoke Therapeutics Q3 EPS $(1.08) Misses $(0.93) Estimate, Sales $11.255M Beat $8.185M Estimate
Stoke Therapeutics (NASDAQ:STOK) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(0.93) by 16.13 percent. This is a 66.15 percent decrease over losses…
3 days ago businesswire.com
Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and…
1 week ago gurufocus.com
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates
[url="]Stoke Therapeutics, Inc.[/url] (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential wit
1 week ago seekingalpha.com
Stoke Therapeutics: The Market Misread A Key FDA Win
Stoke Therapeutics is positioned for a pivotal 2027 readout of zorevunersen, potentially the first disease-modifying Dravet syndrome therapy. STOK's cash runway extends to early 2028, supported by…
2 weeks ago businesswire.com
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and…
-
2 weeks ago benzinga.com
Stoke Therapeutics Presents Data For STK-002 Supporting Disease-Modifying Potential In Autosomal Dominant Optic Atrophy At AAO 2026 Annual Meeting
–ADOA is the most common inherited optic nerve disorder and is primarily caused by variants in the OPA1 gene that result in insufficient levels of OPA1 protein, leading to progressive and…
2 weeks ago businesswire.com
Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today…
3 weeks ago businesswire.com
Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today…
3 weeks ago gurufocus.com
Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicin
3 weeks ago businesswire.com
Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and…
1 month ago defenseworld.net
Stoke Therapeutics, Inc. $STOK Shares Newly Acquired by Corient Private Wealth LP
Corient Private Wealth LP purchased a new stake in Stoke Therapeutics, Inc. (NASDAQ: STOK) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased…
1 month ago businesswire.com
Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and…
1 month ago defenseworld.net
Squarepoint Ops LLC Acquires Shares of 29,310 Stoke Therapeutics, Inc. $STOK
Squarepoint Ops LLC acquired a new position in Stoke Therapeutics, Inc. (NASDAQ: STOK) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission.…
1 month ago businesswire.com
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and…
-
1 month ago benzinga.com
Stoke, Biogen Report Lasting Seizure Reductions In Dravet Syndrome Study
Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (NASDAQ:BIIB) today…
1 month ago gurufocus.com
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16t
[url="]Stoke Therapeutics, Inc.[/url] (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with
1 month ago businesswire.com
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with…
2 months ago businesswire.com
Stoke Therapeutics to Present at the Cantor Global Healthcare Conference
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and…
-
2 months ago benzinga.com
Stoke Therapeutics, Biogen Present Data On Zorevunersen As Treatment For Dravet Syndrome At 16th European Epilepsy Congress
Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today…
-
2 months ago benzinga.com
JP Morgan Reinstates Overweight on Stoke Therapeutics, Announces $40 Price Target
JP Morgan analyst Jessica Fye reinstates Stoke Therapeutics (NASDAQ:STOK) with a Overweight and announces $40 price target.
2 months ago defenseworld.net
Bank of America Corp DE Buys 336,931 Shares of Stoke Therapeutics, Inc. $STOK
Bank of America Corp DE lifted its stake in shares of Stoke Therapeutics, Inc. (NASDAQ: STOK) by 163.4% in the first quarter, according to the company in its most recent filing with the SEC. The fund…
2 months ago businesswire.com
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and…
-
2 months ago benzinga.com
Guggenheim Reiterates Buy on Stoke Therapeutics, Maintains $60 Price Target
Guggenheim analyst Yatin Suneja reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $60 price target.
2 months ago benzinga.com
These Analysts Revise Their Forecasts On Stoke Therapeutics After Q2 Results
Stoke Therapeutics (STOK) reported mixed Q2 results with losses of 93 cents per share and sales of $9.325 million. Analysts have mixed opinions.
-
2 months ago benzinga.com
Wedbush Maintains Outperform on Stoke Therapeutics, Raises Price Target to $40
Wedbush analyst Laura Chico maintains Stoke Therapeutics (NASDAQ:STOK) with a Outperform and raises the price target from $38 to $40.
-
2 months ago benzinga.com
Canaccord Genuity Maintains Buy on Stoke Therapeutics, Lowers Price Target to $58
Canaccord Genuity analyst Sumant Kulkarni maintains Stoke Therapeutics (NASDAQ:STOK) with a Buy and lowers the price target from $60 to $58.
-
3 months ago benzinga.com
Stoke Therapeutics Files Prospectus For Up To $200M ATM Stock Offering; Replaces Prior Program After Selling 4.7M Shares For $146.4M In Net Proceeds
Up to $200,000,000Common StockWe previously entered into a Controlled Equity OfferingSM Sales Agreement, or the Sales Agreement, with Cantor Fitzgerald & Co., or Cantor, relating to shares of our…
-
3 months ago benzinga.com
Stoke Therapeutics Q2 EPS $(0.93) Misses $(0.80) Estimate, Sales $9.325M Beat $6.044M Estimate
Stoke Therapeutics (NASDAQ:STOK) reported quarterly losses of $(0.93) per share which missed the analyst consensus estimate of $(0.80) by 16.25 percent. This is a 132.5 percent decrease over losses…
-
3 months ago benzinga.com
Goldman Sachs Initiates Coverage On Stoke Therapeutics with Buy Rating, Announces Price Target of $44
Goldman Sachs analyst Kevin Strang initiates coverage on Stoke Therapeutics (NASDAQ:STOK) with a Buy rating and announces Price Target of $44.
-
4 months ago benzinga.com
Stoke Therapeutics Completes Enrollment Of 162 Patients Into Phase 3 EMPEROR Study Of Zorevunersen; Co Plans To Initiate Rolling NDA Submission To FDA In Q1 Of 2027
—Company plans to initiate a rolling U.S. NDA submission to the FDA in the first quarter of 2027——Phase 3 data readout anticipated in the third quarter of 2027 to complete the rolling U.S. NDA…
-
5 months ago benzinga.com
BTIG Reiterates Buy on Stoke Therapeutics, Maintains $39 Price Target
BTIG analyst Thomas Shrader reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $39 price target.
-
5 months ago benzinga.com
Stoke Therapeutics Q1 EPS $(0.79) Beats $(0.84) Estimate, Sales $6.229M Beat $5.880M Estimate.
Stoke Therapeutics (NASDAQ:STOK) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of $(0.84) by 5.95 percent. This is a 141.58 percent decrease over earnings…
7 months ago benzinga.com
Semtech To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Tuesday
Wall Street analysts changed outlook on top names: Morgan Stanley raised Lemonade's PT to $85, Mizuho cut Canadian Solar's PT to $19, Piper Sandler raised Tandem Diabetes' PT to $33, Stifel increased…
9 months ago benzinga.com
Exelixis, Citigroup And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Exelixis, Citigroup And Other Big Stocks Moving Lower In Monday's Pre-Market Session
9 months ago benzinga.com
Why Bark Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket
Why Bark Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket
10 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
12 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 months ago benzinga.com
Earnings Scheduled For November 4, 2025
Earnings Scheduled For November 4, 2025
-
1 year ago benzinga.com
Earnings Scheduled For August 12, 2025
Earnings Scheduled For August 12, 2025
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
1 year ago benzinga.com
D.R. Horton, IQVIA Holdings, Northrop Grumman And Other Big Stocks Moving Higher On Tuesday
D.R. Horton, IQVIA Holdings, Northrop Grumman And Other Big Stocks Moving Higher On Tuesday
1 year ago benzinga.com
This Verint Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
This Verint Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 311 stocks hit new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 647 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
During Thursday's session, 406 companies made new 52-week lows.